DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
CAMBRIDGE, England and SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- DIOSynVax, a…
Vantage Markets Empowers Local Communities in Indonesia Through #TradeForHope Campaign
PORT VILA, Vanuatu, Jan. 9, 2025 /PRNewswire/ -- Vantage Markets has demonstrated…
Leading the Way: LiuGong’s Global Sustainability Milestones in 2024 and Beyond
LIUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- From pioneering practices to impactful…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
U.S. Food and Drug Administration Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo (nivolumab) Indications1,2
Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor1 Given…
VIVOTEK Wins Double Honors for Its Commitment to Sustainability
TAIPEI, Dec. 26, 2024 /PRNewswire/ -- VIVOTEK (3454-TW), the global leading security…
PureTechs Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately…
J.F. Lehman & Company Raises $2.2 Billion for Oversubscribed Fund VI
NEW YORK, Dec. 10, 2024 /PRNewswire/ -- J.F. Lehman & Company ("JFLCO"),…
Orca Bio Presents Clinical Results on Use of Orca-Q without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
Orca-Q allogeneic T-cell immunotherapy with no GvHD prophylaxis in patients with matched…
MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting
MTL-HBG drug candidate demonstrated best-in-class activity and safety in pre-clinical models Data…